In a
previous article, I outlined the first half of a presentation
which I gave in Liverpool, focusing on investment into businesses
operating in and around the North-West. More specifically, it
addressed the recent review of Inheritance Tax ("IHT")
undertaken by the Office for Tax Simplification ("OTS"),
and the potential implications, if any, which this could have on
qualifying trades, as well as a brief examination into the impact
which the AIM sell-off through Q4 2018 may have had on sentiment
around AIM IHT products.
In this article, I will address the second topic covered in the
presentation: an examination into the effects which the Patient
Capital Review ("PCR") has had on the EIS and VCT market,
and more pertinently the implications which this has had on the due
diligence process in this space.